Medigen Biotechnology (ROCO:3176) Moat Score: 0/10 (As of Jul. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:3176 Medigen Biotechnology Corp ROCO:3176
58 GF Score
Price NT$35.40
GF Value NT$49.63
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Medigen Biotechnology Moat Score?

Medigen Biotechnology has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Medigen Biotechnology has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Medigen Biotechnology might have No Moat - No discernible moat.

Medigen Biotechnology  (ROCO:3176) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Medigen Biotechnology Moat Score Related Terms

ROCO:3176
58GF Score
Medigen Biotechnology Corp ROCO:3176
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Medigen Biotechnology (ROCO:3176) Overvalued in 2026?

Based on GuruFocus' analysis, Medigen Biotechnology stock appears to be undervalued. The current stock price of NT$35.40 is trading 28.7% below its estimated GF Value™ of NT$49.63. GuruFocus considers Medigen Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:3176:

  • Moat Score: 0
  • GF Value™: NT$49.63 vs. price of NT$35.40 (28.7% below fair value)
  • GF Score™: 58/100 with 5 warning signs

No single metric tells the full story. See the ROCO:3176 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medigen Biotechnology Business Description

Address Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560
Medigen Biotechnology Corp is engaged in the research and development of new drugs and vaccines, cytotherapy, nucleic acid testing, and the production and sales of generic drugs, aesthetic medicine products and vaccine-related products. Its segments are the Nucleic acid department, the New drug and vaccine research and development segment, the Cytotherapy department, and the Generic drug, aesthetic medicine product and dietary supplement segment: responsible for production and sales and relevant services of western medicine, aesthetic medicine product, and dietary supplement. The majority of revenue is derived from generic drugs, aesthetic medicine products, and the dietary supplement segment. Geographically, it operates in Taiwan, China, and Other countries with revenue from Taiwan.
58GF Score

Get the complete analysis for ROCO:3176

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$35.40
Price
NT$49.63
GF Value